{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Lymphoblastic+Lymphoma&page=5", "query": { "condition": "Relapsed or Refractory Lymphoblastic Lymphoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 402, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Lymphoblastic+Lymphoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+or+Refractory+Lymphoblastic+Lymphoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:06:40.591Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00098436", "title": "Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "laromustine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vion Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-09", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098436" }, { "nct_id": "NCT01786135", "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Precursor B-cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "SGN-CD19A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 64, "start_date": "2013-02", "completion_date": "2017-02-16", "has_results": false, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786135" }, { "nct_id": "NCT00002521", "title": "Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "syngeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": null, "start_date": "1993-02", "completion_date": "2000-02", "has_results": false, "last_update_posted_date": "2010-10-01", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002521" }, { "nct_id": "NCT01088763", "title": "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood Infratentorial Ependymoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Gonadotroph Adenoma", "Pituitary Basophilic Adenoma", "Pituitary Chromophobe Adenoma", "Pituitary Eosinophilic Adenoma", "Prolactin Secreting Adenoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Pituitary Tumor", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "TSH Secreting Adenoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 129, "start_date": "2010-03", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2014-11-05", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 11, "location_summary": "Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088763" }, { "nct_id": "NCT00004230", "title": "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "captopril", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1999-10", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004230" }, { "nct_id": "NCT01943682", "title": "Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Burkitt Lymphoma", "Diffuse Large Cell Lymphoma", "Gray Zone Lymphoma", "Lymphoblastic Lymphoma", "Anaplastic Large Cell Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 27, "start_date": "2013-09", "completion_date": "2019-04", "has_results": false, "last_update_posted_date": "2020-11-09", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943682" }, { "nct_id": "NCT06934382", "title": "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Acute Lymphoblastic Leukemia/Lymphoma" ], "interventions": [ { "name": "Allogeneic anti-CD7 CAR-T cells (BEAM-201)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stephan Grupp MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "0 Years to 29 Years" }, "enrollment_count": 33, "start_date": "2025-04-29", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06934382" }, { "nct_id": "NCT01331590", "title": "Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Precursor Cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-07", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 2, "location_summary": "Chicago, Illinois • St Louis, Missouri", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331590" }, { "nct_id": "NCT00052520", "title": "Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "staining method", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2002-09", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052520" }, { "nct_id": "NCT00006213", "title": "BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Promyelocytic Leukemia (M3)", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "BMS-214662", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 30, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-23", "last_synced_at": "2026-10-12T23:06:40.591Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006213" } ] }